TY - JOUR
T1 - Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ
T2 - A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
AU - on behalf of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
AU - Dieci, Maria Vittoria
AU - Radosevic-Robin, Nina
AU - Fineberg, Susan
AU - van den Eynden, Gert
AU - Ternes, Nils
AU - Penault-Llorca, Frederique
AU - Pruneri, Giancarlo
AU - D'Alfonso, Timothy M.
AU - Demaria, Sandra
AU - Castaneda, Carlos
AU - Sanchez, Joselyn
AU - Badve, Sunil
AU - Michiels, Stefan
AU - Bossuyt, Veerle
AU - Rojo, Federico
AU - Singh, Baljit
AU - Nielsen, Torsten
AU - Viale, Giuseppe
AU - Kim, Seong Rim
AU - Hewitt, Stephen
AU - Wienert, Stephan
AU - Loibl, Sybille
AU - Rimm, David
AU - Symmans, Fraser
AU - Denkert, Carsten
AU - Adams, Sylvia
AU - Loi, Sherene
AU - Salgado, Roberto
N1 - Publisher Copyright:
© 2017 The Authors
PY - 2018/10
Y1 - 2018/10
N2 - Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.
AB - Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.
KW - Breast cancer
KW - Ductal carcinoma in situ
KW - Neoadjuvant
KW - Residual cancer burden
KW - Residual disease
KW - Tumor-infiltrating lymphocytes
UR - http://www.scopus.com/inward/record.url?scp=85035012871&partnerID=8YFLogxK
U2 - 10.1016/j.semcancer.2017.10.003
DO - 10.1016/j.semcancer.2017.10.003
M3 - Artículo de revisión
C2 - 29024776
AN - SCOPUS:85035012871
SN - 1044-579X
VL - 52
SP - 16
EP - 25
JO - Seminars in Cancer Biology
JF - Seminars in Cancer Biology
ER -
